Division of Surgical Clinics, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Division of Surgical Clinics, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
An Bras Dermatol. 2024 Nov-Dec;99(6):847-862. doi: 10.1016/j.abd.2024.01.002. Epub 2024 Jul 15.
Platelet-rich plasma (PRP) has been progressively more used in androgenetic alopecia (AGA).
The authors aimed to evaluate PRP efficacy compared to placebo in AGA.
A comprehensive search was conducted across seven databases, until 01/04/2023. Randomized clinical trials focusing on AGA and PRP use to increase hair density were included. Patients aged between 15 and 63 years, diagnosed with AGA characterized by Norwood I‒VII and Ludwig I‒III scales, were included. Studies with a sample size <10, lacking PRP processing method, focusing on complementary therapies or other alopecias, were excluded. The authors conducted subgroup analysis for activator, spin method, study design, risk of bias, and gender. Meta-regression was conducted for activator, spin method, design, and gender. The authors used GRADEpro to assess evidence certainty and the RoB-2 tool for risk of bias. Asymmetry was measured through a Funnel plot followed by Egger's test. The protocol was registered at PROSPERO (CRD42023407334).
The authors screened 555 registers and included fourteen studies involving 431 patients for qualitative synthesis, with 13 studies included in the meta-analysis. Meta-analysis demonstrated a mean difference of 27.55 hairs/cm and 95% CI (14.04; 41.06), I = 95.99%, p < 0.05. Hair diameter meta-analysis presented a mean difference of 2.02 μm, 95% CI (-0.85 μm; 4.88 μm), and I = 77.11% (p = 0.02). That is, low quality evidence.
Studies were highly heterogeneous, of low quality, and presented evident publication bias.
Highly heterogeneous studies with publication bias suggest PRP effectively increases hair density in AGA, so further high-quality randomized clinical trials are recommended to strengthen the evidence.
富含血小板的血浆(PRP)在雄激素性脱发(AGA)中被越来越多地应用。
作者旨在评估 PRP 在 AGA 中的疗效与安慰剂相比。
全面检索了七个数据库,截至 2023 年 4 月 1 日。纳入了专注于使用 PRP 增加头发密度的 AGA 和 PRP 治疗的随机临床试验。纳入年龄在 15 至 63 岁之间、被诊断为 NORWOOD I-VII 和 LUDWIG I-III 分级的 AGA 患者。排除样本量<10 的研究、缺乏 PRP 处理方法的研究、专注于补充疗法或其他脱发的研究。作者对激活剂、旋转方法、研究设计、偏倚风险和性别进行了亚组分析。对激活剂、旋转方法、设计和性别进行了 meta 回归分析。作者使用 GRADEpro 评估证据确定性,使用 RoB-2 工具评估偏倚风险。通过漏斗图和 Egger 检验测量不对称性。该方案已在 PROSPERO(CRD42023407334)注册。
作者筛选了 555 个登记册,纳入了 14 项涉及 431 名患者的研究进行定性综合分析,13 项研究纳入了荟萃分析。荟萃分析显示,平均差异为 27.55 根/平方厘米,95%置信区间(14.04;41.06),I=95.99%,p<0.05。头发直径荟萃分析显示,平均差异为 2.02 微米,95%置信区间(-0.85 微米;4.88 微米),I=77.11%(p=0.02)。这意味着证据质量低。
研究高度异质,质量低,存在明显的发表偏倚。
存在发表偏倚的高度异质性研究表明 PRP 可有效增加 AGA 中的头发密度,因此建议开展高质量的随机临床试验以加强证据。